Investigational drug · Phase 3
AP301
Also called: Solnatide for reconstitution for for
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease).
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "AP301"
First trial start
2018
May 23, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AP301", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hyperphosphatemia
- Chronic Kidney Disease, Receiving Dialysis
- ESRD (End-Stage Renal Disease)
- Dialysis
- ARDS
Approved drugs for the same conditions: Chronic kidney disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "AP301" as an intervention, largest first.
- AP301 Efficacy and Safety in Chinese Dialysis Patients With HyperphosphatemiaPivotal-lookingCompleted
Alebund PharmaceuticalsIndustry
NCT07030595 · 474 participants · Start Jun 12, 2023 · Primary completion Oct 2, 2024
Drug: AP301; Sevelamer carbonate (Renvela®) and 1 more · For: ESRD (End Stage Renal Disease); Chronic Kidney Disease(CKD); Hyperphosphatemia and 3 more
Sites: Beijing, China; Jilin City, China; Xiamen, China · 50 sites in all
- A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and ChinaPivotal-lookingRecruiting
Alebund PharmaceuticalsIndustry
NCT06933472 · 264 participants (planned) · Start Jun 13, 2025 · Primary completion Jun 20, 2026
Drug: AP301; AP301 Low Dose · For: Hyperphosphatemia; Chronic Kidney Disease, Receiving Dialysis; ESRD (End-Stage Renal Disease) and 1 more
Sites: Granada Hills, California; San Dimas, California; Lone Tree, Colorado · 42 sites in all
- A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis PatientsPivotal-lookingCompleted
Shanghai Alebund Pharmaceuticals LimitedIndustry
NCT04551300 · 158 participants · Start Oct 13, 2020 · Primary completion Jun 30, 2022
Drug: VS-505; Sevelamer Carbonate · For: Hyperphosphatemia
Sites: Beijing, China; Xiamen, China; Guilin, China · 23 sites in all
Apeptico Forschung und Entwicklung GmbHIndustry
NCT03567577 · 92 participants · Start May 23, 2018 · Primary completion Dec 27, 2024
Drug: Solnatide 25 mg powder for reconstitution for solution for inhalation; 0.9% Saline Solution · For: ARDS
Sites: Vienna, Austria; Graz, Austria; Innsbruck, Austria · 15 sites in all
Apeptico Forschung und Entwicklung GmbHIndustry
NCT01627613 · 40 participants · Start Jul 2012 · Primary completion May 2014
Drug: AP301; Saline solution · For: Acute Lung Injury
Sites: Vienna, Austria
Alebund Pty LtdIndustry
NCT06100627 · 32 participants · Start Jan 11, 2024 · Primary completion Feb 8, 2024
Drug: AP301 · For: Healthy Subjects
Sites: Melbourne, Australia
Apeptico Forschung und Entwicklung GmbHIndustry
NCT02095626 · 20 participants · Start Jun 2013 · Primary completion Mar 2015
Drug: AP-301; saline solution · For: PGD Primary Graft Dysfunction
Sites: Vienna, Austria
Newest research
PubMed records naming it or its code names, newest first.
- Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis.
Zhuang B, Gan L, Liu B, et al. · Nephrol Dial Transplant 2024
- Direct endothelial ENaC activation mitigates vasculopathy induced by SARS-CoV2 spike protein.
Romero MJ, Yue Q, Singla B, et al. · Front Immunol 2023
- Conformational ensemble of the TNF-derived peptide solnatide in solution.
Martin-Malpartida P, Arrastia-Casado S, Farrera-Sinfreu J, et al. · Comput Struct Biotechnol J 2022
- Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate-to-severe ARDS-a randomized, placebo-controlled, double-blind trial.
Schmid B, Kredel M, Ullrich R, et al. · Trials 2021
- Pharmacological agents for adults with acute respiratory distress syndrome.
Lewis SR, Pritchard MW, Thomas CM, et al. · Cochrane Database Syst Rev 2019
- Targeting resolution of pulmonary edema in primary graft dysfunction after lung transplantation: Is inhaled AP301 the answer?
Ware LB · J Heart Lung Transplant 2017
Also in development for Hyperphosphatemia
- AP306Phase 21 trial
R1 Therapeutics · Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.